SAT0627-HPR SEXUAL QUALITY OF LIFE IN 39 FEMALE PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES
Authors: B. Heřmánková, M. Špiritović, S. Oreska, H. Štorkánová, M. Klein, K. Pavelka, L. Šenolt, H. Mann, J. Vencovský, M. Tomčík
Journal: Annals of the Rheumatic Diseases (2020)

Background: Symptoms related to idiopathic inflammatory myopathies (IIM) such as weakness of skeletal muscles, pulmonary and articular involvement may have a negative impact on all aspects of life including sexual life. Objectives: To assess sexual functioning in female IIM patients compared to age-/sex-matched healthy controls (HC) and to analyze the potential impact of clinical features on sexual health. Methods: In total, 39 women (29 currently have a partner) with IIM [mean age: 54.7, disease duration: 11.8 years, dermatomyositis (DM, 19)/ polymyositis (PM, 16)/ necrotizing myopathy (IMNM, 3)/ inclusion body myositis (IBM, 1)] and 39 healthy controls (30 currently have a partner, mean age: 54.7 years) without rheumatic diseases filled in 11 well-established and validated questionnaires assessing sexual function (FSFI, SFQ28, BISFW), quality of sexual life (SQoL-F), pelvic floor function (PISQ-12, PFIQ-7), fatigue (FIS, MAF), physical activity (HAP), and depression (BDI-II). A standard laboratory testing was performed. Data are presented as mean ± SEM. Results: Patients with IIM reported significantly higher prevalence and greater severity of sexual dysfunction (FSFI, BISF-W, SFQ28) and worse sexual quality of life (SQoL-F) compared to HC (table 1). Worse scores in IIM patients were associated with increased inflammation [CRP: FSFI (r=-0.378, p=0.0190), SFQ-28 Satisfaction domain (r=-0.346, p=0.0356), SQoL-F (r=-0.331, p=0,0479], greater muscle weakness of m. gluteus maximus/ m. gluteus medius/ m. iliopsoas [FSFI: (r=0.426, p=0.0368), (r=0.370, p=0.0368), (r=0.394, p=0.0252), SQoL-F (r=0.504, p=0.0044), (r=0.421, p=0.0204), (r=0.462, p=0.0100)], greater fatigue [FIS: FSFI (r=-0.358, p=0.0154), BISF-W (r=-0.415, p=0.0084), SQoL-F (r=-0.327, p=0.0481)], more severe depression [BDI-II: FSFI Arousal domain (r=-0.357, p=0.0299)], deteriorated quality of life [HAQ: BISF-W (r=-0.464, p=0.0033)], and worse ability to perform physical activities [HAP: FSFI (r=0.405, p=0.0105), BISF-W (r=0.480, p=0.0019)]. No associations were found with disease duration, prednisone dose or serum levels of muscle enzymes. Table 1. Questionnaire: score range (meaning ) IIM (n=39 ) HC (n=39 ) p-value FSFI : Female Sexual Function Index: 2(worst)-36(best) 15.7±2.1 20.7±2.0 p=0.0421 BISF-W : Brief Index of Sexual Function for Women: -16 (worst)-75(best) 14.6±2.8 24.5±3.0 p=0.0134 SFQ28 Desire domain : Sexual Function Questionnaire: 5(worst)-31(best) 11.7±1.0 14.7±1.0 p=0.0457 PISQ–12 : Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form: 0(best)-48(worst) 14.9±0.8 10.1±1.0 p=0.0005 SQoL-F: Sexual Quality of Life Questionnaire – Female: 0(worst)-100(best) 31.8±5.1 80.7±2.5 p&lt;0.0001 PFIQ7 : Pelvic Floor Distress Inventory Questionnaire – short form 7: 0(best)-300(worst) 24.7±6.3 10.1±2.7 p=0.0820 FIS: Fatigue Impact Scale: 0(best)-160(worst) 55.3±5.5 33.2±4.3 p=0.0025 MAF: Multidimensional Assessment of Fatigue Scale: 1(best)-50(worst) 22.0±2.0 15.7±1.4 p=0.0021 BDI-II: Beck’s Depression Inventory II: 0(best)-63(worst) 12.8±1.5 6.6±0.9 p=0.0013 HAP: Human Activity Profile – adjusted activity score: 0(worst)-94(best) 51.0±3.5 80.2±1.6 p&lt;0.0001 HAQ: Health Assessment Questionnaire: 0(best)-3(worst) 1.1±0.1 0.1±0.1 p&lt;0.0001 Conclusion: Women with IIM reported significantly impaired sexual function and sexual quality of life compared to age-matched healthy controls. Worse scores in IIM were associated with disease activity, physical activity, fatigue, depression and quality of life. Acknowledgments: Supported by MHCR 023728, SVV 260373 and GAUK 1578119. Disclosure of Interests: Barbora Heřmánková: None declared, Maja Špiritović: None declared, Sabina Oreska: None declared, Hana Štorkánová: None declared, Martin Klein: None declared, Karel Pavelka Consultant of: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Speakers bureau: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Ladislav Šenolt: None declared, Heřman Mann: None declared, Jiří Vencovský: None declared, Michal Tomčík: None declared